RT Journal Article
T1 Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries
A1 Recher, Christian
A1 Roellig, Christoph
A1 Berard, Emilie
A1 Bertoli, Sarah
A1 Dumas, Pierre-Yves
A1 Tavitian, Suzanne
A1 Kramer, Michael
A1 Serve, Hubert
A1 Bornhaeuser, Martin
A1 Platzbecker, Uwe
A1 Mueller-Tidow, Carsten
A1 Baldus, Claudia D.
A1 Martinez-Cuadron, David
A1 Serrano, Josefina
A1 Martinez-Sanchez, Pilar
A1 Rodriguez Arboli, Eduardo
A1 Gil, Cristina
A1 Bergua, Juan
A1 Bernal, Teresa
A1 de la Fuente Burguera, Adolfo
A1 Delabesse, Eric
A1 Bidet, Audrey
A1 Pigneux, Arnaud
A1 Montesinos, Pau
K1 Acute myeloid-leukemia
K1 Newly-diagnosed aml
K1 Epigenetic therapy
K1 Elderly-patients
K1 Early death
K1 Azacitidine
K1 Management
K1 Venetoclax
K1 Regimens
K1 Care
AB The outcome of acute myeloid leukemia patients aged 70 years or older is poor. Defining the best treatment option remains controversial especially when choosing between intensive chemotherapy and hypomethylating agents. We set up a multicentric European database collecting data of 3 700 newly diagnosed acute myeloid leukemia patients >= 70 years. The primary objective was to compare overall survival in patients selected for intensive chemotherapy (n = 1199) or hypomethylating agents (n = 1073). With a median follow-up of 49.5 months, the median overall survival was 10.9 (95% CI: 9.7-11.6) and 9.2 months (95% CI: 8.3-10.2) with chemotherapy and hypomethylating agents, respectively. Complete remission or complete remission with incomplete hematologic recovery was 56.1% and 19.7% with chemotherapy and hypomethylating agents, respectively (P = 70 years. The primary objective was to compare overall survival in patients selected for intensive chemotherapy (n = 1199) or hypomethylating agents (n = 1073). With a median follow-up of 49.5 months, the median overall survival was 10.9 (95% CI: 9.7-11.6) and 9.2 months (95% CI: 8.3-10.2) with chemotherapy and hypomethylating agents, respectively. Complete remission or complete remission with incomplete hematologic recovery was 56.1% and 19.7% with chemotherapy and hypomethylating agents, respectively (P
PB Springernature
SN 0887-6924
YR 2021
FD 2021-11-13
LK https://hdl.handle.net/10668/25507
UL https://hdl.handle.net/10668/25507
LA en
DS RISalud
RD Apr 7, 2025